Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00175370 |
Recruitment Status :
Completed
First Posted : September 15, 2005
Last Update Posted : June 20, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients admitted into the Intensive Care Unit (ICU) have an intravenous (IV) catheter (small plastic tube) placed in their vein. Very occasionally (4 times out of 100) the insertion of an intravenous catheter may cause an infection in the blood. It has been shown that the removal of the catheter and the insertion of a new one at a new site helps to get rid of this infection. Sometimes, antibiotics are also given.
Vancomycin is the antibiotic given intravenously (into the vein) to treat these catheter-related infections. At Vancouver General Hospital, some physicians may not give any vancomycin at all whereas others may treat with intravenous (IV) vancomycin for one to fourteen days.
Since there are a lack of data to support the length of IV vancomycin therapy, the investigators would like to find out if two days of IV vancomycin are as good as seven days.
Therefore, the purpose of this study is to determine if two days of IV vancomycin are as good as seven days for the treatment of catheter-related infections in the blood.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Staphylococcal Infections | Drug: Vancomycin | Not Applicable |
INTRODUCTION: Intravascular device associated bacteremia due to coagulase negative staphylococcus has become the most common nosocomial bacteremia. Despite its prevalence, no prospective study has investigated how these infections should be treated. Removal of the intravascular device is associated with a reduction in recurrence rate from 20% to 3% but the required duration of vancomycin therapy is not known. We propose to test the hypothesis that, following removal of the intravascular device, treatment with 2 days of vancomycin is equivalent to 7 days of vancomycin.
INTERVENTION: Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used.
MEASUREMENTS: Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus; Removal of Catheter Followed by 2 Days Compared With 7 Days Intravenous Vancomycin |
Study Start Date : | September 2000 |
Actual Primary Completion Date : | December 2007 |
Actual Study Completion Date : | December 2007 |

- Drug: Vancomycin
Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
- The primary outcome measurement will be the proportion of patients with early bacteriological failure [ Time Frame: Nine days ]
- Early bacteriologic failure [ Time Frame: Nine days ]
- Recovery in blood culture of an isolate with same antibiogram, biotype and PFGE type as the initial bacteria, from any blood culture, up to 9 days following IVD removal [ Time Frame: Nine days ]
- The secondary endpoint will be the proportion of patients with clinical failure, late bacteriologic failure and recurrent bacteremia. [ Time Frame: Nine days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients admitted to the ICU who require treatment for suspected or documented intravascular device associated (IVDA) bacteremia due to coagulase-negative staphylococci (CNS). Suspected IVDA bacteremia due to CNS is defined as finding of gram positive cocci in blood in a patient with either an intravascular device (IVD) in situ or within 24 hours of catheter removal, with clinical signs of sepsis:
- two signs of systemic inflammatory response syndrome (SIRS): heart rate (HR) > 90, Temp > 38 or < 36, white blood cell (WBC) > 12 or < 4, respiratory rate (RR) > 20 or pCO2 < 32; and
- with no obvious source of bacteremia other than the IVD.
Exclusion Criteria:
- Underlying valvular heart disease
- Prosthetic valve or graft
- A history of infectious endocarditis
- Bone marrow transplant recipient
- Neutropenia (< 0.5 X 10^9/L)
- Solid organ transplant recipient
- Known hypersensitivity to vancomycin
- Calculated creatinine clearance < 25 ml/min

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00175370
Canada, British Columbia | |
Vancouver General Hospital Intensive Care Unit | |
Vancouver, British Columbia, Canada, V5Z 1M9 |
Principal Investigator: | Jane de Lemos, MD | University of British Columbia |
Responsible Party: | Dr. Jane de Lemos, University of British Columbia |
ClinicalTrials.gov Identifier: | NCT00175370 |
Other Study ID Numbers: |
C00-0106 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | June 20, 2008 |
Last Verified: | June 2008 |
Vancomycin Coagulase Negative Staphylococcus Central Venous Catheter Bloodstream infection CNS bloodstream infection |
Infections Communicable Diseases Staphylococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Sepsis |
Disease Attributes Pathologic Processes Systemic Inflammatory Response Syndrome Inflammation Vancomycin Anti-Bacterial Agents Anti-Infective Agents |